Journal article
Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
International journal of radiation oncology, biology, physics, v 22(1)
1992
PMID: 1309204
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Twenty-five patients with primary presentation of malignant astrocytoma, astrocytoma with anaplastic foci, and glioblastoma multiforme were treated with surgical resection and definitive radiation therapy followed by intravenous or infra-arterial administration of Iodine-125 labeled monoclonal antibody-425, which binds specifically to human epidermal growth factor receptor. The patients presented with primary untreated disease, positive contrast enhanced computed tomography scans of the brain, and compatible clinical symptoms. In this Phase II clinical trial, the patients had surgical debulking or biopsy followed by definitively administered external beam radiation therapy and one or multiple doses (35 to 90 mCi per infusion) of radiolabeled antibody. The total cumulative doses ranged from 40 to 224 mCi. The administrations of the radiolabeled antibody were performed in most cases 4–6 weeks following completion of the primary surgery and radiation therapy. Ten patients had astrocytoma with anaplastic foci and 15 had glioblastoma multiforme. No significant life-threatening toxicities were observed during this trial. At 1 year 60% of the patients with astrocytoma with anaplastic foci or glioblastoma multiforme are alive. The median survival for both groups was 15.6 months.
Metrics
Details
- Title
- Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
- Creators
- Luther W. Brady - Hahnemann University HospitalCurtis Miyamoto - Hahnemann University HospitalDavid V. Woo - Hahnemann University HospitalMichael Rackover - Hahnemann University HospitalJacqueline Emrich - Hahnemann University HospitalHans Bender - Hahnemann University HospitalSimin DadparvarZenon Steplewski - The Wistar InstituteHilary Koprowski - The Wistar InstitutePerry Black - Hahnemann University HospitalBette Lazzaro - The Wistar InstituteSomnath Nair - Hahnemann University HospitalThomas McCormack - Hahnemann University HospitalJoseph Nieves - Hahnemann University HospitalMark Morabito - Hahnemann University HospitalJeffrey Eshleman - Hahnemann University Hospital
- Publication Details
- International journal of radiation oncology, biology, physics, v 22(1)
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine); [Retired Faculty]
- Web of Science ID
- WOS:A1992GU93200035
- Scopus ID
- 2-s2.0-0026599333
- Other Identifier
- 991019184305204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging